Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | PKM | P14618 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | GRIK1 | P39086 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.66 |
| ▸ | SERPINE1 | P05121 | 3/20 | 0.60 |
| ▸ | MDM4 | O15151 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.58 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.58 |
| ▸ | DHODH | Q02127 | 1/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.55 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18595102 | 0.85 | KMT2A (0.72) | KMT2AMEN1PKMMAPTGRIK1 | |
| SCHEMBL6096421 | 0.84 | MEN1 (0.74) | KMT2AMEN1PKMMAPTGRIK1 | |
| SCHEMBL1954779 | 0.84 | MEN1 (0.72) | KMT2AMEN1PKMMAPTGRIK1 | |
| SCHEMBL15067280 | 0.84 | MEN1 (0.72) | KMT2AMEN1PKMMAPTGRIK1 | |
| SCHEMBL414754 | 0.82 | MEN1 (0.83) | KMT2AMEN1PKMMAPTGRIK1 | |
| SCHEMBL31053873 | 0.82 | MEN1 (0.83) | KMT2AMEN1PKMMAPTGRIK1 | |
| SCHEMBL2271365 | 0.82 | PKM (0.70) | KMT2AMEN1PKMMAPTGRIK1 | |
| SCHEMBL637477 | 0.82 | KMT2A (0.70) | KMT2AMEN1PKMMAPTGRIK1 | |
| SCHEMBL14075414 | 0.82 | MEN1 (0.70) | KMT2AMEN1PKMMAPTGRIK1 | |
| SCHEMBL14907131 | 0.82 | KDM4E (0.81) | KMT2AMEN1PKMMAPTGRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150105436-A1 | Methods and Assays for Detecting and Treating Hypoglycemia | BIOCRINE AB (SE) | 2015-04-16 | — | — | US | claimed |
| US-20130217738-A1 | Methods and Assays for Detecting and Treating Hypoglycemia | BIOCRINE AB (SE) | 2013-08-22 | — | — | US | claimed |
| US-20110021584-A1 | Methods and Assays for Detecting and Treating Hypoglycemia | UNIVERSITY OF MIAMI (US) | 2011-01-27 | — | — | US | claimed |
| EP-2254568-A2 | METHODS AND ASSAYS FOR DETECTING AND TREATING HYPOGLYCEMIA | University of Miami (US) | 2010-12-01 | — | — | EP | claimed |
| WO-2009114718-A2 | METHODS AND ASSAYS FOR DETECTING AND TREATING HYPOGLYCEMIA | UNIVERSITY OF MIAMI (US) | 2009-09-17 | — | — | WO | claimed |
| US-7488756-B2 | Use of non-competitive and selective GluR5 antagonists as glutamate receptor modulating compounds | NEUROSEARCH A/S (DK) | 2009-02-10 | — | — | US | claimed |
| US-20040048889-A1 | Use of non-competitive and selective glur5 antagonists as gultamate receptor modulating compounds | NEUROSEARCH A/S (DK) | 2004-03-11 | — | — | US | claimed |
| EP-1355640-A1 | USE OF NON-COMPETITIVE AND SELECTIVE GLUR5 ANTAGONISTS AS GLUTAMATE RECEPTOR MODULATING COMPOUNDS | NEUROSEARCH A/S (DK) | 2003-10-29 | — | — | EP | claimed |
| WO-2002058691-A1 | USE OF NON-COMPETITIVE AND SELECTIVE GLUR5 ANTAGONISTS AS GLUTAMATE RECEPTOR MODULATING COMPOUNDS | NEUROSEARCH A/S (DK) | 2002-08-01 | — | — | WO | claimed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| US-11732262-B2 | Use of FUBP1 inhibitors for treating hepatitis B virus infection | UNIVERSITE CLAUDE BERNARD LYON I (FR) | 2023-08-22 | — | — | US | disclosed |
| US-11732262-B2 | Use of FUBP1 inhibitors for treating hepatitis B virus infection | UNIVERSITE CLAUDE BERNARD LYON I (FR) | 2023-08-22 | — | — | US | disclosed |
| US-20210024934-A1 | USE OF FUBP1 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION | UNIVERSITE CLAUDE BERNARD LYON I (FR) | 2021-01-28 | — | — | US | disclosed |
| WO-2007019346-A1 | BENZOTHIAZOLES AND THIAZOLOPYRIDINES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019344-A1 | IMIDAZO [2,1-B] THIAYOLE DERIVATIVES AS SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20040048889-A1 | Use of non-competitive and selective glur5 antagonists as gultamate receptor modulating compounds | NEUROSEARCH A/S (DK) | 2004-03-11 | — | — | US | disclosed |
| EP-1355640-A1 | USE OF NON-COMPETITIVE AND SELECTIVE GLUR5 ANTAGONISTS AS GLUTAMATE RECEPTOR MODULATING COMPOUNDS | NEUROSEARCH A/S (DK) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002058691-A1 | USE OF NON-COMPETITIVE AND SELECTIVE GLUR5 ANTAGONISTS AS GLUTAMATE RECEPTOR MODULATING COMPOUNDS | NEUROSEARCH A/S (DK) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024934-A1 | USE OF FUBP1 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION | FUBP1, FUBP3, SERBP1 | KMT2A 2358/4885MEN1 4075/4885PKM 4275/4885 |
| US-11732262-B2 | Use of FUBP1 inhibitors for treating hepatitis B virus infection | FUBP1, FUBP3, SERBP1 | KMT2A 2358/4885MEN1 4075/4885PKM 4275/4885 |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRT1, SIRT3, SIRT2 | KMT2A 137/4885MEN1 3453/4885PKM 2447/4885 |
| US-20040048889-A1 | Use of non-competitive and selective glur5 antagonists as gultamate receptor modulating compounds | GRM5, GRIK5, GRIN1 | KMT2A 1332/4885MEN1 4791/4885PKM 3013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.